1. Introduction {#sec1}
===============

Nowadays, the implantable cardioverter-defibrillator (ICD) is the gold standard for the prevention of sudden cardiac death due to ventricular tachyarrhythmias \[[@bib1],[@bib2]\]. Current guidelines recommend ICD implantation for secondary and primary prevention in patients with an established high risk of sudden cardiac death (SCD) \[[@bib3],[@bib4]\]. However, in selected patients, the risk of SCD may be increased only temporarily or cannot be immediately determined. The wearable cardioverter-defibrillator (WCD) has been approved for clinical practice in 2001 to bridge a period of presumed high risk of SCD \[[@bib5],[@bib6]\]. The 2015 guidelines of the European Society of Cardiology give a IIb, level of evidence C indication for WCD in case of patients with poor left ventricular systolic function who are at risk of sudden arrhythmic death for a limited period but are not candidates for an ICD (i.e. bridge to transplant, bridge to transvenous implant, peripartum cardiomyopathy, active myocarditis, and arrhythmias in the early post-myocardial infarction phase) \[[@bib4]\]. The present study sought to retrospectively analyse our single-centre experience with a relatively small sample of patients treated with WCD.

2. Methods {#sec2}
==========

The current study is a retrospective analysis based on all consecutive WCDs applied between April 2017 and September 2018 in our centre to those patients at risk of sudden arrhythmic death for a limited period and without an immediate indication to ICD implantation.

All patients were fitted with the device, trained in its use, and instructed to wear the device continuously for 3 months (except while bathing). According to the PROLONG study \[[@bib7]\], those patients who presented an increase in left ventricular ejection fraction (LVEF) ≥5% or from 30% to 35% received a prolongation of WCD application. Sites were alerted if a participant wore the device for less than 15 h in a 24-h period (monitored through the device itself).

The database collection includes demographic information, customer call reports and device data, such as reason, compliance and duration of WCD use. Incidences of shock therapy and asystole (defined as ECG signal amplitude below 100 μV for at least 16 s) were reviewed from ECG recordings. Sudden cardiac arrest included both sustained (lasting 30 s) ventricular tachycardia (VT) or ventricular fibrillation (VF), as detected through programmed rate criteria. An exercise test was performed in all patients in order to evaluate the absence of false detection of ventricular arrhythmias by the device.

Compliance with device use for each patient was calculated by averaging the hours used per day of wear. The time to deliver therapy was programmed as follows: 60 s for VT and 25 s for VF. The VT and VF zones were programmed, respectively, \>150 bpm and \>200 bpm in all patients except one, who received a more conservative programmation (VT and VF zone respectively \>170 and \> 220 bpm).

A detailed description of the WCD (LifeVest® device, ZOLL, Pittsburgh, PA, USA) has been provided in prior publications and reviews \[[@bib7],[@bib8]\]. In case of sensed ventricular arrhythmic episodes, the WCD is able to deliver a treatment shock through three self-gelling defibrillation electrodes. The WCD stores data on device usage and all ECGs associated with arrhythmia detection, which are then uploaded to the company server to be reviewed and evaluated by the treating physician.

Categorical variables are expressed as absolute and relative frequencies. Continuous variables are expressed as mean+SD or median and range as appropriate. Statistical analysis was performed using SPSS 20.0.0 (IBM Inc., Armonk, New York, USA).

3. Results {#sec3}
==========

A total of 16 patients (57.7 ± 14.8 years old; 75% males) were enrolled in the study. The characteristics of the study population are listed in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}. As [Fig. 1](#fig1){ref-type="fig"} shows, the underlying reasons for WCD application were: dilated cardiomyopathy with impairment of LVEF following myocardial infarction (n = 4; 25%), myocarditis (n = 4; 25%), chemotherapy (n = 2, 12%), alcohol abuse (n = 1, 6%), and related to unknown causes in 3 patients (19%); in addition, 2 patients (12%) were recruited because of ventricular arrhythmias under diagnostic definition. The patients wore the device for a mean time of 3.1 ± 1.7 months (median: 3 months) and for a mean daily time of 22.3 ± 1.9 h (median 23.3 h). The mean wear time was 91.2 ± 44.1 days.Table 1Clinical characteristics and medical therapy of the study population.Table 1Clinical featuresAge (years)57.7 ± 14.8Male gender12 (75%)Hypertension5 (31%)Dyslipidemia4 (25%)Diabetes5 (31%)**Medical therapy**ACE inhibitors/sartans10 (62%)Beta blockers14 (87%)Amiodarone6 (37%)Sacubitril/valsartan2 (12%)Diuretics13 (81%)MRAs12 (75%)Statins8 (50%)[^1]Table 2Characteristics of the study population.Table 2PatientAgeGenderIndicationsWCD application time (months)Daily average of use (hours)Medical therapyLVEF before (%)LVEF after (%)Outcome\#173maleIschemic DCM323.9ACEi, BB,D,AA,statin3535ICD implantation\#257malePost-myocarditis DCM223.9BB,S/V,D,AA,statin2954no ICD\#357maleIdiopathic DCM223.6BB,amio, D,AA,statin3146no ICD\#467maleIschemic DCM323.7ACEi,BB,D,statin3035ICD implantation\#556femalePost-chemotherapy DCM521.4ACEi,BB,amio,D2642no ICD\#614maleVentricular arrhythmias119.4none6060no ICD\#756malePost-myocarditis DCM819.1ACEi, amio,D,AA1830ICD implantation\#859malePost-myocarditis DCM323.8ACEi,BB,D,AA,statin3437no ICD\#960femalePost-myocarditis DCM223.1ACEi,BB,D,AA2525CRT implantation\#1076femaleIschemic DCM223.9ACEi,BB,amio,D,AA, statin3042no ICD\#1163maleVentricular arrhythmias322.2BB,amio5858ICD implantation\#1245maleIschemic DCM422.7ACEi,BB,D,AA,statin3036no ICD\#1353femalePost-chemotherapy DCM120.6BB,amio,AA3045no ICD\#1479maleIdiopathic DCM323.5ACEi,BB,D,AA3038no ICD\#1552maleIdiopathic DCM423.7BB,S/V,D,AA3045no ICD\#1656maleDCM related to alcohol abuse318.2ACEi,BB,D,AA,statin2340no ICD[^2][^3]Fig. 1The picture shows the underlying conditions for wearable cardioverter-defibrillator application. DCM: dilated cardiomyopathy.Fig. 1

No patients presented sustained ventricular arrhythmias during the observation period; neither appropriate nor inappropriate shocks were delivered by the device. Of note, in 3 patients (19%) the WCD reported episodes of high ventricular rates which the medical review actually labelled as sinus tachycardias. Two patients (12%) had already a story of persistent atrial fibrillation and another one (6%) had a paroxysmal episode of atrial fibrillation during the hospital stay. Of note, 11 patients (69%) exhibited non sustained ventricular tachycardias before WCD application.

Mean LVEF was 32 ± 11% at diagnosis and 42 ± 10% at last follow-up (mean, 3.1 ± 1.7 months; median, 3 months). At last follow up and after the clinical re-evaluation, 11 patients (69%) did not have indication for a definitive ICD. Five patients (31%) underwent ICD implantation, 3 of them received a single-chamber device, another one received a biventricular device and the fourth one a subcutaneous ICD. Finally, one patient (6%) showed a marked reduction in ventricular arrhythmias under therapy with amiodarone and a loop recorder implantation was decided to monitor the patient during the follow up.

4. Discussion {#sec4}
=============

Although the present cohort study is limited by the relatively low number of patients and, subsequently, the absence of malignant arrhythmic events, the following observations can be drawn: (1) no inappropriate shocks released by the device occurred; (2) the mean wear time per day was high; (3) the rate of patients who did not present indications for ICD at last follow up was high, especially for those patients who received a prolonged WCD application period.

Some studies reported the occurrence of inappropriate shock delivered by WCD. Olgin et al. \[[@bib9]\] reported a rate of 0.6% of inappropriate shock (9/1524) in a recente, large, randomized and prospective study investigating the usefulness of WCD in the early phase after acute myocardial infarction. In the PROLONG study \[[@bib7]\], Duncker et al. did not report any inappropriate shocks in 156 patients with newly diagnosed LVEF≤ 35%. Our patient population did not experience any inappropriate shock but this finding is limited by the very small number of patients. However, in our protocol an exercise test was systematically performed in all patients in order to evaluate the absence of false detection of ventricular arrhythmias by the device. This might have hypothetically been useful to avoid inappropriate shocks during the follow-up period.

In our study the mean wear time per day was high when compared with the literature; for instance, the PROLONG study \[[@bib7]\] and Olgin et al. \[[@bib9]\] reported a mean wear time per day of 21.7 ± 4 and 14.0 ± 9, respectively. The latter did not find a significant lower rate of arrythmic death or total mortality in patients with WCD compared with those without WCD. However, the authors interestingly reported in the as-treated analysis that patients who chose to wore the device, having a better compliance and higher mean wear time per day, presented a significant reduction both in arrhythmic death and in total mortality (respectively, p = 0.03 and p \< 0.001). Therefore, the compliance and the mean wear time might probably be crucial for the decrease of arrhythmic and overall mortality. In our study the compliance and mean wear time per day were satisfactory; however, as no arrhythmic events occurred in our patient population, any inference about these aspects and malignant arrhythmic episode and mortality could not be done.

The rate of patients who did not implant ICD at the end of the WCD period was high (69%); these data are in line with the findings of the PROLONG study \[[@bib7]\], which reported that 63% of initial patients with LVEF \<35% experienced a significant improvement in the left ventricular systolic function and avoided a permanent ICD implantation. Of note, the prolongation of WCD period \>3 months because of initial increase of LVEF resulted in an higher proportion of patients with a recovery of LVEF \>35%. In the present study, 4 patients received WCD for \>3 months because of a partial increase of LVEF; as shown in [Tables 1](#tbl1){ref-type="table"} and 3 of them (75%) presented an improvement of LVEF over 35% and indications for ICD implantations faded out in these patients. Finally, the WCD might also be an helpful tool for the detection of supraventricular arrhythmias during the follow up of these patients.

It should be specified that although the current practice accepts a LVEF cut off of 35% is based on MADIT II \[[@bib10]\] and SCDHeFT \[[@bib11]\] trials, the arrhythmic risk is not binary but it is present through the entire continuum of LVEF with a reverse trend, the more the LVEF increases the more arrhythmic risk decreases but it never abolishes \[[@bib12]\].

The relative small number of patients and heterogeneity of the underlying aetiologies represent important limitations. Moreover, another limitation is that patients did not receive a further arrhythmic risk stratification beyond the LVEF assessment.

In conclusion, the WCD may represent a useful tool for patients with poor LVEF who are at risk of sudden arrhythmic death for a limited period but are not candidates for a definitive ICD. The present study reports an optimal profile of compliance after adequate training of the patient; neither arrhythmic death nor inappropriate shock occurred. The proportion of patients with an improvement of LVEF\> 35% beyond the WCD period was considerable as already shown by previous studies. However, as the present study includes a small population and no arrhythmic events occurred during the follow period, no conclusions about arrhythmic detection and treatment of this device can be drawn. Larger, randomized, controlled studies are needed to confirm the effectiveness of this technology and to identify the subgroup of patients who might benefit from this technology.
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[^1]: ACE: angiotensin-converting enzyme; MRA: mineralocorticoid receptor antagonist.

[^2]: WCD: wearable cardioverter-defibrillator, LVEF: left ventricular ejection fraction, DCM: dilated cardiomyopathy, ACEi: angiotensin converting enzyme inhibitors.

[^3]: BB: beta blockers, D: diuretics, AA: anti-aldosteronics, ICD: implantable cardioverter-defibrillator, S/V: sacubitril/valsartan, amio: amiodaron, CRT: cardiac resynchronization therapy.
